Sphingosine kinase (SK) is an innovative molecular target for therapy because of its critical role in sphingolipid metabolism, which is known to regulate adipocyte metabolism. Apogee’s lead compound, opaganib, inhibits SK2, DES-1 and GCS and has shown an excellent safety profile to date in nearly 500 human patients in clinical trials for cancer and severe COVID, with patients being on study well over a year.
replica relojes,replica fake rolex rolex airking,rolex datejust,rolex day date,rolex daytona,rolex explorer,rolex rolex replica rolex masterpiece,rolex milgauss,rolex …
Opaganib:
- is the only “drug-like” SK inhibitor reported to date;
- is orally bioavailable and has excellent pharmacokinetics;
- has an excellent safety profile;
- inhibits obesity, glucose intolerance, fatty liver disease, rebound weight gain with semaglutide and hypercholesterolemia
- inhibits VEGF-induced vascular leakage in vivo;
- inhibits diabetes-induced retinal vascular leakage in vivo;
- inhibits collagen- and adjuvant-induced arthritis in vivo;
- inhibits DSS- and TNBS-induced inflammatory bowel disease in vivo;
- inhibits experimental lupus in vivo;
- inhibits liver ischemia-reperfusion injury in vivo; and
- inhibits kidney ischemia-reperfusion injury in vivo
- inhibits lung inflammation and fibrosis.
Partnering
We are interested in advancing opagnib for obesity and related conditions.
Intellectual Property
The first US Patent (US 7,338,961) entitled “Sphingosine Kinase Inhibitors”, which covers opaganib, issued on 03/04/2008.
Our current intellectual property is a pending Methods of Use patent for opaganib to treat obesity and related co-morbidities.